PatientsVille.com Logo


Phosphate Medical Research Studies

Up-to-date List of Phosphate Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Phosphate Medical Research Studies

Rank Status Study
1 Not yet recruiting Effect of a Phosphate Modified Diet on Phosphate Balance and Phosphate Metabolism in Predialysis Patients Stage 3-4
Condition: Chronic Kidney Disease
Interventions: Other: Diet with Phosphate containing additives;   Other: Diet without Phosphate containing additives
Outcome Measures: Phosphate balance;   p-Phosphate;   p-PTH;   p-Calcium;   FGF23;   p-25(OH)D;   Calcium-Phosphate product;   p-alkaline phosphatase
2 Recruiting Development of a 'Phosphate Counting Program'
Condition: End Stage Renal Disease
Interventions: Other: iTouch Phosphate counting program;   Other: Usual Care
Outcome Measure: Serum Phosphate
3 Not yet recruiting Investigating a New Way of Giving Medicine to Newborn and Preterm Babies
Conditions: Hypophosphataemia;   Osteopenia of Prematurity
Interventions: Drug: Oral thin film therapy (Potassium acid Phosphate oral thin films);   Drug: Standard therapy (Potassium acid Phosphate oral solution)
Outcome Measures: Serum Phosphate;   Age-appropriateness
4 Not yet recruiting Two Phosphate taRGets in End-stage Renal Disease Trial (TARGET)
Condition: End-stage Renal Disease
Interventions: Drug: Calcium carbonate ( Intensive Phosphate control);   Drug: Calcium carbonate (Liberalized Phosphate control)
Outcome Measures: Serum Phosphate concentration;   Number of patients who successfully achieved target serum P at week 26 based on the arm to which they were randomized;   Treatment compliance as defined by taking the study medication at least 80% of the time;   Number of serious adverse events;   Number of hospitalizations for vascular reasons that are unrelated to dialysis access;   Proportion of patients with a vascular death or non-fatal vascular event;   Proportion of patients developing serum calcium > 2.60 mmol/L;   Number of fractures;   Number of patients developing calcific uremic arteriolopathy (ie, calciphylaxis);   Change in quality-of-life
5 Unknown  A Study Comparing Combination Clindamycin Phosphate/Tretinoin Gel Alone Versus With Benzoyl Peroxide Foaming Cloths for Facial Acne
Condition: Acne Vulgaris
Interventions: Drug: clindamycin Phosphate 1.2%/tretinoin 0.025% gel alone;   Drug: clindamycin Phosphate 1.2%/tretinoin 0.025% gel plus benzoyl peroxide 6% foaming cloths
Outcome Measures: Change in PGA scores of patients using combination clindamycin Phosphate 1.2%/tretinoin 0.025% gel with or without benzoyl peroxide 6% foaming cloths for facial acne;   Change in Postinflammatory hyperpigmentation score at each study visit and from baseline to final visit.;   Total number of adverse events.;   Change in Subject Self Assessment Scoring Scale;   Change in Acne-Specific Quality of Life Questionnaire (Acne-QoL)
6 Recruiting Treatment for Calcium Phosphate Kidney Stone Disease
Condition: Calcium Phosphate Kidney Stones
Interventions: Drug: Placebo;   Dietary Supplement: Citric Acid;   Dietary Supplement: Potassium Citrate;   Drug: Indapamide
Outcome Measure: Urinary calcium Phosphate saturation
7 Recruiting Polycaprolactone / Tricalcium Phosphate (PCL/TCP) v Titanium Orbital Implant : Randomised Trial
Conditions: Fractures;   Enophthalmos;   Diplopia
Interventions: Device: Polycaprolactone / Tri-Calcium Phosphate;   Device: Titanium Mesh
Outcome Measures: Enophthalmos;   Diplopia;   motility of the globe
8 Unknown  Safety and Efficacy of Pyridoxal 5' -Phosphate in the Treatment of Tardive Dyskinesia
Condition: Tardive Dyskinesia
Interventions: Drug: Pyridoxal 5'-Phosphate;   Drug: Placebo
Outcome Measures: The primary outcome measure will be a reduction in the total AIMS score for items 1 through 7 (facial and oral movements, extremity movements and trunk movements) across treatment groups. .;   An AIMS score reduction (items 1-7) across arms over course of study amongst completers; determine whether the proportion of responders differs between treatment arms; a reduction in the AIMS score, items 1 - 7 total, across treatment arms.
9 Unknown  A Study of Epirubicin With Estramustine Phosphate and Celecoxib for the Treatment of Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: Epirubicin;   Drug: Estramustine Phosphate;   Drug: Celecoxib
Outcome Measures: Determine the effect of epirubicin with estramustine Phosphate and celecoxib on PSA and objective response in patients with HRPC;   Evaluate the toxicity of the combination of epirubicin with estramustine Phosphate and celecoxib in patients with stage D3 prostate cancer.;   Determine the effects of this regimen on quality of life.;   Determine the survival of the patients treated with the proposed regimen.
10 Recruiting A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS)
Condition: Lambert Eaton Myasthenic Syndrome
Interventions: Drug: Amifampridine Phosphate;   Drug: Placebo
Outcome Measures: Change from Baseline Quantitative Myasthenia Gravis (QMG)at 14 days;   Change in SGI score;   Change from Baseline Timed 25 Foot Walking Test (T25FW)at 14 days;   Change in CGI-I score
11 Recruiting To Compare the Efficacy and Safety of Clindamycin Phosphate 1.2% / Benzoyl Peroxide 5% Gel of CHL Versus DUAC® Gel
Condition: Acne Vulgaris
Interventions: Drug: Clindamycin Phosphate 1.2% / Benzoyl Peroxide 5% Gel;   Drug: DUAC® Gel;   Drug: Placebo
Outcome Measures: Mean percent change from baseline to week 11 (study Day 77) for inflammatory (papules and pustules) lesions.;   Mean percent change from baseline to week 11 in the non-inflammatory lesion count;   Proportion of subjects with a clinical response of "success" at week 11
12 Not yet recruiting Ridge Preservation With New Class of Osteoplastic Materials
Conditions: Tooth Extraction;   Atrophy of Edentulous Alveolar Ridge
Interventions: Device: Octacalcium Phosphate;   Device: Bio-Oss;   Device: Tricalcium Phosphate
Outcome Measures: The changes of bone level between baseline and 3 months post-extraction at the time of implantation;   Percent new vital bone formation
13 Recruiting Open Label Study of Pharmacokinetics of Prototype Formulations of OZ439 Administered With Piperaquine Phosphate in the Fasted State to Healthy Subjects
Condition: Malaria
Interventions: Drug: Prototype 1: OZ439 800 mg and piperaquine Phosphate 960 mg as powder in bottle;   Drug: Prototype 2: OZ439 800 mg and piperaquine Phosphate 960 mg as powder in bottle;   Drug: Prototype 3: OZ439 800 mg and piperaquine Phosphate 960 mg as powder in bottle
Outcome Measure: Area under the plasma concentration versus time curve (AUC 0-inf) extrapolated to infinity of OZ439 prototype formulations and PQP when co-administered in the fasted state
14 Recruiting Panama and El Salvador Children's Oseltamivir Study
Conditions: Influenza;   Human Influenza
Interventions: Drug: Oseltamivir Phosphate suspension;   Drug: Placebo
Outcome Measures: Length of hospitalization;   Time to resolution of increased work of breathing;   Time to resolution of hypoxia;   Incidence of new onset respiratory failure 24 hours or more after first dose of study medication;   Incidence of admission to intensive care unit 24 hours or more after first dose of study medication;   Incidence of death 24 hours or more after first dose of study medication;   Time to non-detectable influenza virus by viral culture and non-detectable influenza viral RNA by RT-PCR;   Proportion of children with oseltamivir resistant virus detected during or after oseltamivir Phosphate treatment who had oseltamivir susceptible virus infection at enrollment;   Proportion of participants experiencing adverse events (including severe and non-severe)
15 Unknown  Erythrocytes-Mediated Delivery Of Dexamethasone 21-Phosphate In Steroid-Dependent Ulcerative Colitis
Condition: Ulcerative Colitis
Intervention: Drug: Dexamethasone 21-Phosphate
Outcome Measures: The proportion of patients able to discontinue oral corticosteroids while maintaining clinical remission or stable condition;   The proportion of patients with disappearance of steroid-related events;   The modification of biochemical and endoscopic parameters;   The pharmacokinetics of Dex 21-P loaded into red blood cells
16 Recruiting Tricalcium Phosphate and Chitosan as Bone Regenerator Versus Autologous Graft in Surgery for Mandibular Fracture
Condition: Mandibular Fractures
Interventions: Procedure: Tricalcium Phosphate / Chitosan;   Procedure: Autologous Graft
Outcome Measures: Bone density determination in regenerated bone.;   Classification of mandibular fracture;   Edema;   Postoperative infection.;   Defect Size
17 Recruiting Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Total Body Irradiation, and Donor Stem Cell Transplant Followed By Cyclosporine and Mycophenolate Mofetil in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome
Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Childhood Myelodysplastic Syndromes;   Chronic Myelomonocytic Leukemia;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Excess Blasts in Transformation;   Refractory Anemia With Ringed Sideroblasts;   Refractory Cytopenia With Multilineage Dysplasia;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes
Interventions: Radiation: iodine I 131 monoclonal antibody BC8;   Drug: fludarabine Phosphate;   Radiation: total-body irradiation;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Drug: cyclosporine;   Drug: mycophenolate mofetil
Outcome Measures: Incidence of dose-limiting toxicities to determine MTD of radiation delivered to normal organ by iodine I 131 monoclonal antibody BC8;   Rates of transplant-related mortality for patients receiving iodine I 131 monoclonal antibody BC8 when combined with 2 Gy TBI + CSP/MMF;   Disease response in patients receiving iodine I 131 monoclonal antibody BC8 combined with fludarabine Phosphate, 2 Gy TBI, CSP, MMR and HLA-matched related or unrelated allogeneic HSCT;   Disease-free survival in patients receiving iodine I 131 monoclonal antibody BC8 combined with fludarabine Phosphate, 2 Gy TBI, CSP, MMR and HLA-matched related or unrelated allogeneic HSCT;   Rates of donor chimerism and graft-versus-host disease
18 Recruiting Ruxolitinib Phosphate (Oral JAK Inhibitor INCB18424) in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin Lymphoma
Conditions: Peripheral T-cell Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma
Interventions: Drug: oral JAK inhibitor INCB18424;   Other: laboratory biomarker analysis;   Other: pharmacological study
Outcome Measures: Number of patients achieving overall response rate;   Incidence of treatment-emerged adverse events (new or worsening from baseline) as summarized by severity and type according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0;   Duration of response;   Progression-free survival;   Overall survival (OS)
19 Recruiting Comparison of Bioactive Glass and Beta-Tricalcium Phosphate as Bone Graft Substitute
Condition: Bone Neoplasm
Interventions: Device: Bioactive glass;   Device: Beta-tricalcium Phosphate (ChronOs);   Procedure: Autograft;   Procedure: Allograft (frozen femoral head)
Outcome Measures: Stratum I: Hand-grip strength test;   Stratum II: Healing of cortical bone window based on CT scan evaluation;   Biomaterial incorporation assessed with radiographs;   Pain intensity (VAS);   Stratum I: DASH-questionnaire;   RAND-36;   Surgical wound healing;   Soft tissue complications;   Bone complications
20 Recruiting Treosulfan and Fludarabine Phosphate With or Without Total Body Irradiation Before Donor Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome
Conditions: Childhood Myelodysplastic Syndromes;   Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Previously Treated Myelodysplastic Syndromes
Interventions: Drug: treosulfan;   Drug: fludarabine Phosphate;   Radiation: total-body irradiation;   Procedure: peripheral blood stem cell transplantation;   Procedure: allogeneic bone marrow transplantation;   Other: laboratory biomarker analysis
Outcome Measures: Progression free survival (PFS);   Change in gene expression profiles;   Relapse risk as measured by degree of change in gene expression profiles;   Incidence of relapse/progression;   Non-relapse mortality (NRM);   Overall Survival (OS);   Incidence of acute GVHD, graded by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0;   Incidence of chronic GVHD graded by the NCI CTCAE version 4.0

These studies may lead to new treatments and are adding insight into Phosphate etiology and treatment.

A major focus of Phosphate research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.

Discuss Phosphate